Kyruus vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 72)
Kyruus logo

Kyruus

LeaderHealthcare

Provider Data Management & Care Access

Kyruus Health connects 500K+ providers across 1,400 hospitals and 100+ health plan brands; launched AI provider matching on AWS Bedrock with Claude 3.5 Sonnet; partnered with Healthgrades and Google Cloud in 2025.

AI VisibilityBeta
Overall Score
B72
Category Rank
#104 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
74
Gemini
68

About

Kyruus Health is the leading care access platform in the United States, connecting patients and health plan members to the right providers through a combination of provider data management, intelligent search, and AI-powered matching. The platform serves over 500,000 providers across 1,400 hospitals, 550 medical groups, and 100+ health plan brands — making it the de facto infrastructure for provider directory management and patient-facing provider search across much of the U.S. healthcare system. Kyruus Health''s solutions include provider directory management, consumer-facing search experiences, appointment scheduling enablement, and payer-side member engagement tools.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

72
Overall Score
93
#104
Category Rank
#1
86
AI Consensus
80
stable
Trend
stable
73
ChatGPT
94
74
Perplexity
89
68
Gemini
94
73
Claude
92
72
Grok
98

Key Details

Category
Provider Data Management & Care Access
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.